News

Corbus Pharmaceuticals Expands Its Portfolio With Hundreds of Potential New Agents from Jenrin Discovery

Corbus Pharmaceuticals has acquired from Jenrin Discovery more than 600 compounds designed to target the endocannabinoid system, including CRB-4001 for the treatment of fibrotic diseases affecting the lungs, liver, heart, and kidney. The endocannabinoid system is associated with the resolution (or shutting off) of the inflammatory response, which…

Cedars-Sinai Given $12M to Study IPF, Chronic Lung Allograft Dysfunction

The National Institutes of Health (NIH) has granted $12 million to researchers at Cedars-Sinai Medical Center to continue studying two lung diseases — idiopathic pulmonary fibrosis and chronic lung allograft dysfunction. Idiopathic pulmonary fibrosis (IPF) is characterized by progressive scarring of lung tissue which leads to difficulty breathing. Chronic lung allograft dysfunction is a complication…

FDA Puts FibroGen’s Pamrevlumab on Fast Track as IPF Treatment

FibroGen’s investigational compound pamrevlumab has received fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). The agency’s decision follows review of the double-blind PRAISE Phase 2b study (NCT01890265) results, which showed that, over 48 weeks, intravenous…

PFF Suggests Ways to Recognize Pulmonary Fibrosis Awareness Month

September is recognized as Pulmonary Fibrosis (PF) Awareness Month, and the Pulmonary Fibrosis Foundation (PFF) is suggesting a host of ways to get involved in increasing awareness for the disease. Last year, PFF’s awareness efforts on social media reached 915,000 people. This year, the organization hopes to increase that…